Genus plc (LSE:GNS) is in focus on 13 October 2026 as investors assess the latest company-specific developments and the outlook for the FTSE 250. Genus is attracting attention as investors assess its genetics-led growth model, including breeding technology, genetic improvement and licensing income. Its …
GSK plc (LSE:GSK) is in focus on 13 October 2026 because investors are weighing company-specific developments alongside the wider direction of UK equities. The central question is whether its operating performance can translate into durable earnings, cash flow and shareholder value. For a listed …
Haleon (LSE:HLN) is a healthcare stock in the FTSE 100, with investor attention centred on consumer-health brand demand, pricing and category growth across oral health and wellness.
CVS Group is in focus as investors digest its latest full-year performance and assess the next phase of growth across the UK and Australia. For the year ended 30 June 2026, revenue increased 5.9% to £712.8 million, like-for-like sales rose 2.1%, and adjusted EBITDA …
AstraZeneca PLC (LSE:AZN) is in focus on 13 October 2026 because investors are weighing company-specific developments alongside the wider direction of UK equities. The central question is whether its operating performance can translate into durable earnings, cash flow and shareholder value. For a listed …
ConvaTec Group (LSE:CTEC) is a healthcare stock in the FTSE 100, with investor attention centred on demand for advanced wound care and recurring medical products.
NIOX develops and sells point-of-care devices that measure fractional exhaled nitric oxide, a marker of type 2 airway inflammation used in the diagnosis and management of asthma. Its products are used by clinicians in primary and specialist care, and the company also earns trial-related …
Ondine is a Canadian life sciences group listed on AIM. It develops light-activated antimicrobial therapies. Its lead product, Steriwave, is a nasal photodisinfection treatment designed to reduce hospital infections, including surgical site infections. Steriwave is authorised in Canada, the UK and certain other markets. …
OptiBiotix develops and commercialises products and ingredients aimed at improving health through the gut microbiome. Its main commercial products include SlimBiome, a weight management ingredient, and the SweetBiotix platform, which focuses on prebiotic fibres. It sells to partners in multiple regions, including Asia, Australia …
The company develops and sells diagnostic tests linked to nutrition and wellbeing, with a particular focus on food intolerance testing. Its products are designed to help practitioners and consumers identify foods that may be associated with symptoms, so that diets can be adjusted. The …